Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
90.16 EUR | +0.65% |
|
+2.51% | +0.41% |
06-27 | CAC40: caution prevails ahead of crucial deadlines | CF |
06-27 | CAC40: consolidates solo, OAT/Bund spread widens to 81Pb | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.41% | 120B | - | ||
+55.32% | 815B | C+ | ||
+44.05% | 641B | B | ||
-6.75% | 352B | C+ | ||
+13.56% | 314B | B- | ||
+10.68% | 303B | C+ | ||
+16.57% | 242B | B+ | ||
+2.04% | 224B | A+ | ||
+13.31% | 218B | B- | ||
+8.48% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- SNW Stock
- Ratings Sanofi